IL2 and type 1 diabetes mellitus: In vivo expanded Tregs in diseases such as T1D, SLE and ALS treated with low-dose IL-2 stimulation display upregulation of CD25, GITR, CTLA-4, Ki67, Helios, CD39, CD45R0, CCR7 and a memory phenotype, accompanied by enhanced activation and a subsequent increase in suppressive function [207] (Figure 5).